33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1/2 dose escalation study of NUV-422, a potent inhibitor of cyclin-dependent kinases 2, 4, and 6, in recurrent or refractory (r/r) high-grade gliomas (HGG) and solid tumors
    Meeting Abstract

    Wen, P. Y.; Ahnert, J. R.; Powderly, J. D.; Colman, H.; Matheny, S. L.; Golsorkhi, A. A.; Bihani, T.; Zhang, Y.; Kaley, T. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Results for patients with muscle-invasive bladder cancer (MIBC) in the CheckMate 274 trial
    Meeting Abstract

    Witjes, A. A.; Bajorin, D. F.; Galsky, M. D.; Gschwend, J. E.; Tomita, Y.; Lebret, T.; Pérez-Valderrama, B.; Bamias, A.; Collette, S.; Zhang, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study
    Meeting Abstract

    Voss, M. H.; Powles, T.; McGregor, B. A.; Porta, C.; Grünwald, V.; Merchan, J. R.; Rolland, F.; Maroto-Rey, P.; Goh, J. C.; Xing, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Neighborhood socioeconomic disadvantage, tobacco use, and cessation indicators among adults with cancer in the United States: Results from 10 ECOG-ACRIN trials
    Meeting Abstract

    Walter, A. W.; Lee, J. W.; Gareen, I. F.; Kircher, S. M.; Herman, B. A.; Streck, J. M.; Kumar, S.; Mayer, I. A.; Saba, N. F.; Neal, J. W.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical activity of pembrolizumab monotherapy in diffuse malignant peritoneal mesothelioma
    Meeting Abstract

    Wang, X.; Offin, M.; Roshkovan, L.; Miura, J.; Ginsberg, M. S.; Ciunci, C. A.; Egger, J. V.; Walker, S.; Cercek, A.; Litzky, L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Long-term results of a phase 2 trial of crenolanib combined with 7+3 chemotherapy in adults with newly diagnosed FLT3 mutant AML
    Meeting Abstract

    Wang, E. S.; Goldberg, A. D.; Walter, R. B.; Collins, R.; Stone, R. M.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Use of real-world data (RWD) to assess the utility of cell-free circulating tumor DNA (cfDNA) in identifying resistance to early treatment in advanced breast cancer (aBC)
    Meeting Abstract

    Wander, S. A.; Weipert, C.; Liao, J.; Zhang, N.; Razavi, P.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI
    Meeting Abstract

    Usmani, S. Z.; Martin, T. G.; Berdeja, J. G.; Jakubowiak, A. J.; Agha, M. E.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A. M.; Munshi, N. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel
    Meeting Abstract

    Vandris, P.; Chao, K.; Baggott, C.; Phillips, C. L.; Qayed, M.; Rossoff, J.; Lim, S. J. S.; Winestone, L. E.; Stefanski, H. E.; Talano, J. A. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • [(177)Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial
    Meeting Abstract

    Vaishampayan, N.; Morris, M. J.; Krause, B. J.; Vogelzang, N. J.; Kendi, A. T.; Nordquist, L. T.; Calais, J.; Nagarajah, J.; Beer, T. M.; El-Haddad, G.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save